• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris

    BIOSPACE

    Teva`s troubled plant seen to create injectable drug shortages

    FIERCEPHARMA

    ADCETRIS Combination Significantly Improves Overall Survival in Hodgkin Lymphoma

    BUSINESSWIRE

    Seagen Announces Preliminary Results from Phase 2 Trial of ADCETRIS

    BUSINESSWIRE

    Enforcement Report - Week of March 3, 2021

    FDA

    European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD

    BUSINESSWIRE

    US FDA accepts sBLA & grants priority review status for Adcetris

    PHARMABIZ

    Will subgroup stumbles for Adcetris hurt its sales potential?

    FIERCE PHARMA

    FDA approves Eisai`s drug Halaven for type of soft tissue cancer

    FDA

    Array`s skin cancer drug succeeds in late-stage study

    REUTERS

    CytRx Announces Completion of Enrollment in Pivotal Global Ph3 Trial Ahead

    PR NEWS WIRE

    Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.

    FIERCE PHARMA MFG

    Hospira Inc., Ongoing Class III recall of Dacarbazine, Injection, USP, 200mg, vials packaged in individual cartons, Rx only, Manufactured by Hospira Australia 1 Lexia Place, Mulgrave, Victoria Australia 3170. NDC 61703-327-22. because of Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.